The Scottish-born CEO of Pfizer Inc., Ian Read, has revamped the US-based drug maker and turned it into a Wall Street darling over the past five years via a series of moderate-sized acquisitions, spin-offs and strategic cost-cutting moves – but his next acquisition, if allowed by US authorities, seems likely to cement his reputation as a major deal-maker.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?